Delivery Order SPE2DB20D1109-SPE2DB25FP65A
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $3,760.90 delivery order to AmerisourceBergen Drug Corp for 500 mg vials of Dalvance, an antibiotic pharmaceutical product. This competitively awarded, firm fixed-price contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child delivery order, this award falls under the company's larger...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency for 500 mg vials of Dalvance (dalbavancin), a broad-spectrum antibiotic, with a ceiling value of $3,658.32. The contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and was awarded on August 4, 2025. This award carries no set-aside designation, indicating it was competitively awarded through open competition. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,242.43 delivery order to AmerisourceBergen Drug Corp for 500 mg Dalvance vials, with an ultimate completion date of August 14, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a delivery order under the company's broader indefinite delivery contract vehicle with DLA. The work is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $10,284.07 to AmerisourceBergen Drug Corp for 500 mg vials of Dalvance, a broad-spectrum antibiotic commonly used in military and federal healthcare settings. This firm fixed-price delivery order was competitively awarded without set-aside provisions and is scheduled for completion by August 15, 2025. The award represents a single transaction under AmerisourceBergen's larger contract vehicle with DLA Troop Support Medical. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,743.74 to AmerisourceBergen Drug Corp for 500 mg vials of Dalvance, an antibiotic medication, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order was placed with no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $5,377.68 to AmerisourceBergen Drug Corp for the supply of Dalvance 500 mg vials, an antibiotic medication used to treat bacterial skin infections. This firm fixed-price delivery order, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a non-competitive, non-set-aside purchase. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DALVANCE 500 mg vials valued at $9,785.46 under a firm fixed price contract type. The award was made on August 19, 2025, with an ultimate completion date of August 20, 2025, and no set-aside designation was applied. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a pediatric/neonatal antimicrobial supply supporting...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $24,492.53 firm fixed-price delivery order is for the supply of 4567631589 DALVANCE 500 MG VIALS. The contract has an ultimate completion date of March 20, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
- This federal contract award, valued at $8,929.61, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of DALVANCE 500 MG VIALS, a pharmaceutical product, with a completion date of June 13, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $28,127.13, is a Firm Fixed Price Delivery Order for the supply of DALVANCE 500 MG VIALS. The contract has an ultimate completion date of April 3, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP65ADelivery Order
The Defense Logistics Agency awarded a $18,608.38 delivery order to AmerisourceBergen Drug Corp for 500 mg Dalvance vials, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price contract was issued with no set-aside designation. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement valued through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal vendor for military and veteran healthcare systems. The contract will be performed at the company's Conshohocken location. Dalvance (dalbavancin) is an antibiotic used to treat acute bacterial skin and skin structure infections, representing the type of specialized pharmaceutical products the company routinely provides through its comprehensive federal contract portfolio with the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.6k | 8/27/25 |